Literature DB >> 10424317

Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease.

H Kitayama1, K Kiuchi, J Nejima, T Katoh, T Takano, H Hayakawa.   

Abstract

OBJECTIVE: The aim of this study was to examine the hypothesis that long-term treatment with antipsychotic drugs in conventional doses prolongs QTc dispersion and increases ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease.
METHODS: We measured QTc and QTc dispersion and ventricular tachyarrhythmias in 64 patients with schizophrenia, including 59 patients who received psychiatric medications, and five patients who did not receive psychiatric medications, and 45 healthy volunteers. None of the subjects had a history of cardiac disease or showed any abnormality in chest radiograph and transthoracic echocardiographic studies. None of the subjects had electrolyte abnormality. None of the subjects were taking drugs known to influence the QT interval, other than psychiatric medications.
RESULTS: QTc and QTc dispersion were significantly (P < 0.017) increased in patients who received psychiatric medications compared with patients who did not receive psychiatric medications, or with healthy volunteers [QTc: 0.442 (0.029), 0.418 (0.029), 0.417 (0.028) s, QTc dispersion: 0.054 (0.013), 0.038 (0.017), 0.038 (0.009) s]. Daily ventricular premature beats were 183 (689), 77 (23), and 86 (149), respectively. No ventricular tachycardia was observed. There were no correlation between QTc and QTc dispersion and ventricular premature beats.
CONCLUSION: Long-term treatment with antipsychotic drugs in conventional doses prolonged both QTc and QTc dispersion in patients with schizophrenia, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. However, despite the negative findings, ventricular tachyarrhythmias may occur as a rare side-effect of antipsychotic drugs, particularly if a patient has additional risk factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424317     DOI: 10.1007/s002280050626

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Impact of the CSM advice on thioridazine on general practitioner prescribing behaviour in Leeds: time series analysis.

Authors:  Nat M J Wright; Alison J Roberts; Victoria L Allgar; Charlotte N E Tompkins; Darren C Greenwood; Gillian Laurence
Journal:  Br J Gen Pract       Date:  2004-05       Impact factor: 5.386

Review 2.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 5.  Cardiovascular adverse effects of antipsychotic drugs.

Authors:  N A Buckley; P Sanders
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

Review 6.  Pharmacological control of acute agitation: focus on intramuscular preparations.

Authors:  Dan L Zimbroff
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Sudden death of cardiac origin and psychotropic drugs.

Authors:  Quadiri Timour; Dominique Frassati; Jacques Descotes; Philippe Chevalier; Georges Christé; Mohamed Chahine
Journal:  Front Pharmacol       Date:  2012-05-10       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.